Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas
- PMID: 26712866
- DOI: 10.1093/ajcp/aqv014
Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas
Abstract
Objectives: Type II and other high-grade endometrial carcinomas may challenge conventional treatment due to recurrence and metastatic spread and therefore are a persistent clinical dilemma. Effective targeted therapy for these is a goal for clinicians and researchers alike.
Methods: An extensive review of the literature has been performed for obtaining an in-depth understanding of the clinicopathological characteristics, etiologic factors, and molecular profile of these subsets of endometrial carcinoma. Progress made with current and emerging biomarkers for prognosis assessment and therapeutic targeting has been summarized.
Results: There has been a significant increase in research on potential biomarkers of endometrial cancer, and beneficial targeted therapies have been identified.
Conclusions: Clinical trials are leading the charge for substantial gains toward personalized treatment of aggressive endometrial carcinoma subtypes.
Keywords: Biomarkers; Endometrial carcinoma; Targeted therapy.
© American Society for Clinical Pathology, 2016. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Estradiol metabolites as biomarkers of endometrial cancer prognosis after surgery.J Steroid Biochem Mol Biol. 2018 Apr;178:45-54. doi: 10.1016/j.jsbmb.2017.10.021. Epub 2017 Oct 29. J Steroid Biochem Mol Biol. 2018. PMID: 29092787
-
Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.Gynecol Oncol. 2014 Sep;134(3):599-606. doi: 10.1016/j.ygyno.2014.06.026. Epub 2014 Jul 1. Gynecol Oncol. 2014. PMID: 24995579
-
Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.Am J Surg Pathol. 2012 Dec;36(12):1771-81. doi: 10.1097/PAS.0b013e318273591a. Am J Surg Pathol. 2012. PMID: 23154767
-
Advances in the management of recurrent endometrial cancer.Am J Clin Oncol. 2015 Apr;38(2):206-12. doi: 10.1097/COC.0b013e31829a2974. Am J Clin Oncol. 2015. PMID: 23764681 Review.
-
Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.Crit Rev Oncol Hematol. 2006 Jun;58(3):242-56. doi: 10.1016/j.critrevonc.2005.11.002. Epub 2006 Jan 24. Crit Rev Oncol Hematol. 2006. PMID: 16436330 Review.
Cited by
-
Megestrol acetate drives endometrial carcinoma cell senescence via interacting with progesterone receptor B/FOXO1 axis.Exp Biol Med (Maywood). 2021 Nov;246(21):2307-2316. doi: 10.1177/15353702211026566. Epub 2021 Jul 7. Exp Biol Med (Maywood). 2021. PMID: 34233525 Free PMC article.
-
ARG1 Is a Potential Prognostic Marker in Metastatic Endometrial Cancer.Reprod Sci. 2024 Jun;31(6):1632-1641. doi: 10.1007/s43032-024-01493-z. Epub 2024 Feb 22. Reprod Sci. 2024. PMID: 38388922 Free PMC article.
-
Interferon‑stimulated gene 15 promotes progression of endometrial carcinoma and weakens antitumor immune response.Oncol Rep. 2022 Jun;47(6):110. doi: 10.3892/or.2022.8321. Epub 2022 Apr 21. Oncol Rep. 2022. PMID: 35445736 Free PMC article.
-
Immune response characterization of endometrial cancer.Oncotarget. 2019 Jan 29;10(9):982-992. doi: 10.18632/oncotarget.26630. eCollection 2019 Jan 29. Oncotarget. 2019. PMID: 30847026 Free PMC article.
-
MicroRNA-20a-5p inhibits epithelial to mesenchymal transition and invasion of endometrial cancer cells by targeting STAT3.Int J Clin Exp Pathol. 2018 Dec 1;11(12):5715-5724. eCollection 2018. Int J Clin Exp Pathol. 2018. PMID: 31949657 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
